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Environmental transformation processes, including those
occurring in natural and engineered systems, do not necessarily
drastically alter molecular structures of bioactive organic
contaminants. While the majority of generated transformation
products are likely benign, substantial conservation of structure
in transformation products can imply conservation or even
creation of bioactivity across multiple biological end points and
thus incomplete mitigation of ecological risk. Therefore,
focusing solely on parent compound removal for contaminants
of higher relative risk, the most common approach to fate
characterization, provides no mechanistic relationship to
potential biological effects and is inadequate as a comprehen-
sive metric for reduction of ecological risks. Here, we explore
these phenomena for endocrine-active steroid hormones,
focusing on examples of conserved bioactivity and related
implications for fate assessment, regulatory approaches, and
research opportunities.
■ INTRODUCTION
One critical lesson learned from many decades of research is
that organic contaminants do not magically disappear when
discharged to soil, air, or water, even with engineered treatment
before discharge. Unfortunately, contaminants often remain
with us, either as the original parent compound or converted
into transformation products by processes like biodegradation,
chemical oxidation, photolysis, or hydrolysis. Persistent
characteristics are especially likely for some synthetic chemicals
where implicit resistances to transformation are exploited in
molecules to increase their function. Indeed, many of our
foundational examples of unintended consequences arising
from our use of synthetic organic chemicals like pesticides (e.g.,
DDT) or dielectric fluids (e.g., PCBs) result because we did not
accurately define the relationship between their release,
environmental persistence, and potential effects on exposed
organisms until it was too late. Over time, through many
lessons hard won, we now appreciate that characterizing
environmental fates for the millions of chemicals produced,
used, and inevitably discharged to the environment is
important, even though we often have limited, or even no,
insight into potential biological effects arising from exposure.
So where might unintended consequences still exist? What
are the critical exceptions to our generalizations and
assumptions about contaminant fate? While early research
efforts usually examined contaminants like pesticides with
demonstrable adverse effects, recent efforts have explored a
wider variety of organic contaminants. Examples include
pharmaceuticals, personal care products, perfluorinated com-
pounds, and plasticizers (so-called contaminants of emerging
concern or CECs) present in municipal wastewater, urban
stormwater, and/or agricultural runoff. Research on these trace
organics is driven by factors such as their widespread detection
by improved analytical instrumentation, their incomplete
removal in traditional treatment systems, and growing interest
in water reuse, implying potential exposure for recalcitrant
contaminants. Observations of sublethal effects in aquatic
organisms arising from exposure to wastewater-derived steroid
hormones and other endocrine-active contaminants also has
raised concerns, especially with respect to estrogenic endocrine
disruption in fish. This issue in particular exemplifies our
struggle to incorporate the potential for bioactive contaminants
that induce chronic or sublethal effects into risk assessment
paradigms originally constructed to assess exposures to acute
toxicants and carcinogens that tended toward persistence.
Resolving this issue, understanding the degree by which chronic
and sublethal effects alter populations, and identifying
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contaminants most responsible for adverse effects is of primary
importance in accurately evaluating chemical safety.
Here, we discuss one limitation in our understanding of CEC
fate: transformation products of bioactive compounds, like
pharmaceuticals, generated during natural attenuation or
engineered treatment. In particular, we focus on endocrine-
active steroid hormones because of their widespread use as
pharmaceuticals, the extent of available pharmacology knowl-
edge, their demonstrated potency, and their link to sublethal
effects in aquatic organisms. Consequently, we, and others, view
steroidal hormones and their environmental fate and effects as
high priority research areas.1 Furthermore, the combination of
their potency and structure-dependent bioactivity makes them
an excellent case study to examine conservation of bioactivity
through environmental transformations. Bioactive transforma-
tion products can be viewed as environmental designer drugs,
built in nature by some of the same (bio)chemical processes
exploited by pharmaceutical manufacturers for drug discovery
and capable of evading many commonly employed analytical
techniques. Most importantly, their formation poses formidable
challenges to how we evaluate contaminant fate, particularly
with respect to their attenuation. Thus, our objective is to
illustrate underexplored or underappreciated emerging issues
and uncertainties related to transformation products. We also
aim to highlight potential areas where unintended consequen-
ces related to the formation of such environmental designer
drugs in natural and engineered aquatic systems might arise in
the future as a means of better understanding and managing
contaminant risks.
Receptor Agonists and Environmental Bioactivity. In
the U.S., we manufacture over 21 000 human pharmaceutical
products using at least 1200 unique small molecule drugs.2
Over 10% of these drugs target nuclear receptors such as
estrogen (ER), androgen (AR), progesterone (PR), or
glucocorticoid receptors (GR), and include many synthetic
steroids far more potent than their endogenous analogs (17β-
estradiol, testosterone, progesterone, or cortisol). Besides
human pharmaceuticals, potent steroids are widely used in
agriculture,3 and all vertebrates naturally excrete endogenous
steroids with inherent bioactivities.4 Plant steroids such as
phytoestrogens, can also occur widely in aquatic environments,
including WWTP effluent.5 Thus, once accounting for
metabolites and transformation products, there are likely
hundreds of unique steroids discharged to the aquatic
environment at some concentration, even if only a few of
them are measured directly.
In addition to their primary receptor targets, steroids, their
metabolites and transformation products also can have
nontarget, inadvertent interactions (i.e., “side effects”) with a
host of molecular receptors, enzymes and biochemical
pathways. Even binding specific receptors as ligands can alter
the activation of other receptors through cross-talk mecha-
nisms, or impairment of hormone biosynthesis through
feedback pathways. Therefore, we really should not be
surprised by reports that anthropogenic impacts on receiving
waters can include inadvertent up- or down-regulation of
receptor-mediated pathways in aquatic organisms exposed to
these complex mixtures, even at trace levels.6−10 Numerous side
effects typically result from pharmaceutical use in humans,
implying that we should expect bioactive contaminants to
exhibit side effects and nontarget interactions in aquatic
organisms as well.
When examining the literature for field studies, many
examples exist where bioassays indicate widespread or frequent
detection of receptor agonists, yet concurrent chemical analysis
only weakly links these biological responses to specific causative
agents.9,11−14 Unexpected and often unexplained receptor
activities are observed for ER, AR, and, more recently, GR.
For example, Stavreva et al.14 observed GR activity in 27% and
AR activity in 35% of surface waters across 14 states in the
eastern U.S., with chemical analysis unable to account for most
of the observed bioactivity. In another study, widespread and
persistent GR activity in wastewater and wastewater-impacted
receiving waters, even at substantially higher levels than ER or
AR activity,15 could not be explained by chemical analysis of 41
known glucocorticoids. Such discrepancies are even greater
when considering causality in animal end points and
undesirable endocrine-mediated effects like intersex fish,
including masculinized or feminized fish or vitellogenin
induction in male fish observed in some receiving waters.16−20
Until we can explain such observations, we will remain
uncertain about the true relationship between contaminant
exposure and ecological risk, as well as best management
practices to mitigate such effects.
A Potential Role for Transformation Products in
Instances of Unexplained Bioactivity. Linking biological
responses observed at molecular, cellular, organismal, or
population scales to causative agents has long been a significant
problem in ecotoxicology. Contaminants occur in complex
mixtures whose composition varies spatially and temporally,
and we now appreciate that transformation products of
bioactive compounds can themselves retain bioactivity. For
example, of the ∼380 pesticide analytes in a recent survey of
five Swiss rivers, ∼30% of the detected compounds were
transformation products, and assessment of mixture toxicity
was needed to accurately define ecological risk.21 While the vast
majority of transformation products are likely benign, there are
multiple scenarios for product formation and some are more
effective than others at mitigating risk (Figure 1). The simplest
case, and most desirable for mitigation, occurs when loss of
parent concentration is accompanied by formation of known
and innocuous products, thus closing the system’s mass balance
(Figure 1a). Here, transformation results in concurrent
bioactivity removal, and there is a clear degree of reaction
progress where the risks associated with contaminant exposure
attain acceptable levels. We note that even without requisite
product identification, a direct correlation between parent
decay and proportional removal of bioactivity is the default
assumption in current fate models and risk assessment.
Alternatively, transformation products may be identifiable,
thereby closing the system mass balance, yet these products
retain some degree of bioactivity (Figure 1b). In this case,
understanding product bioactivity is critical. Depending on the
specific bioactivity (e.g., 10%, 50% or 100% relative to the
parent) and receptor end point, the risk associated with this
system is only partially, or even not, mitigated by parent
transformation. Currently, this case requires complementary
analytical and toxicological methodologies to appropriately
assess risk. Finally, a third scenario (Figure 1c) is most
challenging, and may be more common than we currently
appreciate, especially when the potential for interactions with
multiple biological end points is considered. Here, not only is
some degree of bioactivity retained but the specific products
responsible for the response remain unexamined or unidenti-
fied. These cases are often characterized by dynamic
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concentration profiles that diverge from trends in bioactivity
measured with in vitro assays. This scenario probably describes
at least some of the aforementioned examples14,15 where GR
activity has been detected via bioassays yet specific causative
agents cannot be identified by targeted analyses. As another
example, Stalter et al.22 observed an increase in developmental
retardation for rainbow trout after ozonation of a membrane-
filtered, municipal wastewater, which they attributed to the
formation of toxic but unknown transformation products.
One risk factor only rarely evaluated is the potential for cross
receptor reactivity where environmental transformations alter
the biological target of the product relative to its parent. Highly
specific receptor interactions (i.e., ER, AR, PR, GR) are derived
from rather subtle but localized structural differences between
steroids. Because the tetracyclic steroid backbone is common to
all of these ligands, simple transformations can alter binding
between these receptors.23,24 For example, some synthetic
progestins like levonorgestrel, norethindrone, and gestodene
are also strong androgens,24 although this androgenic character-
istic would usually not be assessed by study designs focused on
progestogenic characteristics. Steroids also can act concurrently
as agonists and antagonists for multiple receptors.25 This
complexity complicates accurate characterization of environ-
mental risk because single step transformations of progestins,
for example, can yield glucocorticoids or androgens (e.g.,
progesterone dealkylation forms androstenedione) and andro-
gen aromatization yields estrogens. Dose of the parent and/or
transformation product can also be important; some steroids
may bind to a specific receptor at low doses, but multiple
receptors at higher doses. In addition, there are significant
cross-talk mechanisms between receptors and central nervous
system targets that impact endogenous steroid biosynthesis,
clearance and feedback loops. The common use of a single
receptor end point to assess bioactivity upon transformation
may therefore underestimate risk in cases where parents and
products bind to different nuclear receptors. Similarly, cross-
receptor interactions provide a potential explanation for
nonlinear uncertainty in some bioanalytical approaches, as
multiple receptor interactions potentially all modulate a single
adverse outcome such as impaired reproduction.
Examples of Bioactive Transformation Products.
Potent synthetic steroids are examples where only slight
structural modifications relative to their endogenous analogs
can induce drastically higher potency and enable interactions
with multiple receptors, including responses not intuitively
obvious from structural inspection alone. Ethinyl estradiol
(EE2) is perhaps the best known example of a synthetic steroid.
It differs from its endogenous analog 17β-estradiol (E2) only by
a C17 ethyne group, yet is up to 27-fold more potent than E2
in fish.26 As another example, the bioactivity of trenbolone, an
anabolic growth promoter, is not solely defined by its
androgenic properties, but because it also exhibits 37% higher
binding affinity to PR than progesterone and also elicits anti-
GR activity.27
Accordingly, transformations in natural and engineered
systems that only slightly alter contaminant structures can
imply retained bioactivity and thus not fully mitigate exposure.
Table 1 demonstrates some steroid transformations yielding
products of known, measured or probable bioactivities.28−46 As
first examples, there is substantial precedent for glucuronide
deconjugation in biologically active environments, which
regenerates the active parent from an inactive, polar
metabolite.28 Similarly, keto-hydroxy interconversions are
common (e.g., testosterone to androstenedione) and yield
bioactive, and in some cases more potent, products (e.g.,
formation of 17β-estradiol from estrone).28−30
Further examination of the literature reveals additional
laboratory reports of single-step transformations that also
retain receptor binding activity. Methyl inversion during
photolysis of estrone produces lumiestrone, which is 40% as
estrogenic as its parent.37 Photolysis of trenbolone metabolites
yields photohydration products that not only exhibit unique
Figure 1. Potential scenarios for how bioactivity can change with
reaction progress during environmental transformations. Plots show
mass of the parent compound (blue) and identifiable product (green)
on the left vertical axis, while changes in bioactivity (red) are plotted
on the right vertical axis. (a) Case 1 represents the transformation of a
parent compound into a known, identifiable, and nonbioactive product
such that bioactivity scales with parent compound concentration. (b)
In Case 2, the product is known and identifiable, but also bioactive.
Dashed red lines consider how bioactivity would change as a function
of reaction progress when the known product exhibits bioactivity that
is 10%, 50% or 100% of the parent compound’s bioactivity. (c) Case 3
considers the case in which bioactivity diverges from trends in the
measured concentration of parent and product (i.e., the red bioactivity
line increases while concentrations of the parent and the identifiable
product decrease). In this case, unknown (i.e., unidentified) products
must be responsible for the persistent bioactivity.
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bioactivity,40 but also can undergo subsequent dehydration to
regenerate the potent parent steroid at high yield in the dark.41
Yang et al.29 observed 1,2 dehydrogenation of testosterone by
manure-derived bacteria to yield the major product boldenone
(i.e., “1-dehydrotestosterone”), an anabolic steroid with AR
binding affinity 56% greater than testosterone.27 Some
additional reaction pathways are summarized in Table 1, all
of which involve minor to modest structural alterations to yield
products with likely bioactivity. In fact, as best exemplified by
testosterone (Figure 2), there exist many structural modifica-
tions, including some reasonably expected to be environ-
mentally relevant, that retain or create functional groups
Table 1. Reported environmental transformations with known or suspected bioactive steroidal products
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responsible for receptor interactions, even increasing properties
like anabolic activity.47
Thus, we cannot reasonably expect that all transformation
processes will be equally effective at eradicating bioactivity,
complicating risk assessment for instances of persistent
bioactivity upon parent removal. Certain “soft” transformations
inducing only slight structural modifications may be surpris-
ingly ineffective when a molecule’s bioactivity is linked to more
than just highly localized functional groups. Such soft
transformations appear most common for natural attenuation
(e.g., solar photolysis, biodegradation), but may also occur in
some engineered treatment systems. These types of systems
can be conceptualized as “reagent-limited”, typically lacking the
photo- or biochemical energy to induce drastic structural
modifications, much less mineralization. In contrast, “hard”
transformations are those inducing dramatic structural
modifications that extend beyond localized moieties to
encompass changes across the molecule’s entirety (e.g., ring
cleavage in steroids), although several sequential reactions may
be needed to attain extensive structural modification. Such
transformations are more typical during chemical oxidation
processes where oxidants are often dosed beyond the initial
demand to achieve a residual (or excess) concentration.
Conceptual Steps Forward. We propose that accurate
assessment of risk mitigation during transformations of
bioactive contaminants needs to consider whether any
transformation products remain within the “pharmacophore.”
Overington et al.2 defined the pharmacophore as the “ensemble
of steric and electronic features that is necessary to ensure
optimal interactions with a specific biological target structure
and to trigger (or block) its biological response.” This concept
implies that a collection of ligand features collectively explains
the potential for and magnitude of any interaction with
biological targets. Each mode of action or molecular target has
its own pharmacophore (e.g., each nuclear receptor represents a
pharmacophore for steroids). Contaminant interactions with
different molecular targets (i.e., “side effects”) also imply that
promiscuity of pharmacophores is possible and even likely, so
we should not assume that contaminant bioactivity is
necessarily isolated to any single biological end point. Complete
characterization of bioactivity may therefore have to consider
not only pharmacophore retention, but also the evaluation of
distinct and overlapping pharmacophores.
Thus, the potential for adverse ecological risks arises when
contaminants embody a pharmacophore and subsequent
transformations are best characterized by their potential to
destroy (or alternatively preserve) that pharmacophore. It is a
major assumption that transformation processes always reduce
bioactivity by removing key structural attributes of the
pharmacophore. While this is often true and should remain
the initial assumption, those cases of retained or even increased
overall bioactivity in products indicate that a wider context is
necessary. Currently, most fate research and also aspects of the
regulatory process define assessment of environmental fate
largely in terms of “removal”, or the quantitative reduction in
contaminant concentration in any particular system.48 Removal
alone is an imperfect surrogate for the characterization of
environmental fate and ecological risk; it has no implicit link to
any pharmacophore. Thus, we should expect there will be cases
where it overestimates reductions in ecological risk.49 Similarly,
ecological risk assessments utilizing persistence in weight of
evidence evaluations may be missing what is most important: a
quantitative link to bioactivity and hazard for both parent
structures and environmental transformation products.
Possible Solutions and Research Opportunities.
Despite extensive effort, the overall relevance of much research
focused upon defining environmental exposures and persistence
often remains very unclear because it lacks strong links to
biological hazard. This has historically been addressed via
Whole Effluent Toxicity testing as required by U.S. EPA’s
Clean Water Act, where biological testing of wastewater
effluents is used as a surrogate for potential environmental
impacts.50 If toxicity is observed, then a toxicity identification
evaluation (TIE), a biologically guided fractionation of complex
water samples to determine causality, is employed. Unfortu-
nately, TIE bioassays as suggested by the U.S. EPA51 utilize
exclusively acute toxicity end points that do not account for any
subtle biochemical effects associated with endocrine disrupting
chemicals. The U.S. EPA did establish the Endocrine Disruptor
Screening Program (EDSP) after amendments to the Safe
Drinking Water Act and Food Quality Protection Act.52
Although this comprehensive program was developed primarily
to screen commercial chemicals for potential endocrine
impacts, it is painfully slow largely because of the reliance on
animal testing. Notably, the EPA has recently considered the
inclusion of more high-throughput in vitro screening assays as
part of the “EDSP of the 21st Century (EDSP21)”.53 To the
best of the authors’ knowledge, neither of these programs
holistically considers transformation products.
Moving forward, it will be imperative to link molecular
initiating events to chronic and sublethal effects in aquatic
organisms. Such has been the emphasis of the U.S. EPA and the
Organization for Economic Cooperation and Development
(OECD), which promote Adverse Outcome Pathway (AOP)
paradigms for toxicity testing.54 This approach employs high
throughput in vitro receptor based bioassays to screen
chemicals for specific AOPs which, if observed, provide a
tiered process for additional whole animal testing linking
molecular initiating events to population impacts. Utilizing
numerous databases such as TOXCAST, data also can be used
for in silico models with the ultimate goal of reducing animal
testing.52 While AOPs provide the biological linkages between
exposure and adverse effect, there still remains a clear need for
exposure assessments within this process.
In this context, we note that most exposure scenarios in
receiving waters are best defined as a complex mixture of parent
compounds, metabolites and products whose activities may
span several different receptor end points at a range of different
potencies. However, few ecotoxicology study designs focus on
mixture effects or explicitly consider the potential conservation
Figure 2. Structural modifications of testosterone known to increase
the anabolic potency in the steroidal products (used with permission
from Kicman and Gower47).
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of bioactivity through environmental transformations. Aquatic
organisms near wastewater discharges will be exposed mostly to
parent compounds and wastewater-derived transformation
products, while downstream organisms will encounter not
only persistent parents, but also many environmental trans-
formation products generated via natural attenuation. Fur-
thermore, water quality is vastly different and dynamic around
the globe; for instance, seasonal differences can dramatically
change the fate characteristics of a particular chemical within a
watershed. Until we can capture the complexity and dynamics
of these systems with inclusive bioactivity-based character-
izations that provide links to biological relevance, our
understanding of the ecological implications of contaminant
discharge remains incomplete.
Sophisticated chemical analyses such as high-resolution mass
spectrometry and compound specific isotopic analysis will
certainly play an important role in improved fate character-
ization for many contaminants, particularly with respect to
directed characterization of transformation products.55 For
example, using high-resolution mass spectrometry with bioassay
directed fractionation, causative agents can probably be
identified. However, while comprehensive, this technique is
costly and technically advanced, can be limited by the need for
pure standards, and struggles with complex environmental
matrices.
Computational approaches should prove especially valuable
for achieving high throughput screening, both from the
perspective of predicted environmental fate and also for
possible biological characteristics of products as a complete
first pass in silico assessment. Currently, computational fate
approaches are most mature for biotransformation, where tools
like the University of Minnesota’s Biocatalysis/Biodegradation
Database56 can predict probable transformation pathways. The
use of electronic theory to predict transformation products33
also could be expanded and validated to better characterize
contaminant fate. Outputs from computational fate modeling
can subsequently be integrated with in silico tools such as
molecular docking models to investigate conserved bioactivity
within products and mixtures quickly and relatively easily.
Molecular docking tools and high throughput screening
methods are improving rapidly and can have excellent accuracy
for evaluating nuclear receptor interactions and screening
multiple end points.57 Applying these techniques, originally
developed for drug discovery, to environmental research should
be especially promising, although these approaches are limited
to known receptor end points and do miss complex
interactions. Notably, such tools have been proposed for
AOP frameworks to provide in silico linkages between fate,
exposure, and threshold end points, which can be directly
utilized in risk assessments.
We therefore advocate an integrated and collaborative
approach relying on complementary chemical analysis,
bioanalytical tools, and predictive computational approaches
to help understand environmental mixtures and improve TIEs
for the cases lacking identification of causative agents in
bioactive samples. What is the next logical step when
sophisticated chemical analyses cannot identify causative
agents? Based upon themes well developed in the drug
discovery literature, we would argue that causality is probably
best explained by structures similar to known high affinity
ligands because a high affinity backbone structure (i.e., the
steroidal rings) provides the basis of a pharmacophore.
Beginning computational assessments with known high affinity
ligands as parents may intrinsically provide guidance for
subsequent directed analysis of bioactive products. Such a
tool has been developed for the ER by U.S. EPA and is known
as the ER Expert System (ERES). Using an inventory of 893
entries, the model has been proposed as a prioritization
mechanism for Tier 1 testing through the EDSP.58
This integrated approach will also help to develop criteria for
identifying high risk contaminants and prioritizing pollutant
classes and functionalities likely to generate bioactive products.
Such prioritization schemes can be based upon traditional
aspects including parent compound potency but also
incorporate reactivity to account for product risks. This may
improve the analysis of complex wastewater or agricultural
runoff mixtures by providing analytical targets for products and
metabolites. Classically, we have viewed limited persistence and
rapid reaction rates as desirable fate outcomes, yet there will be
instances where these characteristics will be disadvantageous
when they create persistent, bioactive products that are difficult
to detect via directed analyses. To prioritize transformations,
our focus should be placed on identifying potent compounds
highly susceptible to single step environmental transformations
with reasonably persistent and bioactive products. We should
also alter our experimental and modeling approaches to
reconsider product stability for high risk contaminants. Most
experimental data gathered using fixed conditions and relatively
short time scales provide little insight of long-term product fate,
particularly when subsequently exposed to dynamic environ-
ments with redox gradients, diurnal (light/dark) cycles, and
diverse reactive entities in both natural and engineered systems.
For example, while crude, there is much to be gained by
subjecting product mixtures to stark contrasts, such as
comparing stability at low pH versus high pH, aerobic versus
anoxic redox conditions, light versus dark systems, or in the
presence of reagents used in treatment (e.g., free chlorine).
These relatively simple diagnostics would help to define the
spectrum of reactivity expected for product mixtures across
diverse aquatic systems.
We would be remiss not to consider the role of engineered
treatment in controlling the risks associated with bioactive
transformation products, specifically because a significant
portion of trace organic loading to the environment occurs
through wastewater effluent subjected to physical, biological,
and/or chemical processes. Transformation products are
expected in treated effluent; many organic chemicals are
relatively recalcitrant to biological treatment or simply
transformed into more stable structures, and organic
contaminants are rarely mineralized during disinfection and
oxidation processes. For example, most water is disinfected with
chlorine, yet the degree to which chlorine can oxidize organic
contaminants is highly dependent on water quality and
operational conditions. The extent of transformation in
chlorine systems can be critical with respect to formation of
bioactive products. A notable example is Hu et al.,39 who
observed estrogenic products after 17β-estradiol chlorination
and identified several chlorinated derivatives (e.g., 2,4-dichloro-
17β-estradiol and 2,4-dichloro-estrone) likely responsible for
persistent bioactivity. Considering alternative oxidants, studies
indicate that while ozone can be highly effective for
estrogenicity attenuation in wastewater, the resulting by-
products can be toxic, though also biodegradable and thus
relatively easily removed.22 In fact, it is only with chemical
oxidation via advanced oxidation processes that the majority of
trace organics appear well attenuated, although the dissolved
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organic carbon is only meagerly reduced.59 Collectively,
research to date demonstrates that both weak and powerful
oxidants, as well as UV light, can lead to the formation of
transformation products that retain, accentuate, or create
bioactivity during water treatment. Considering the increasing
interest in the use of ozonation and other forms of oxidation for
chemical contaminant attenuation, more research is warranted
to identify, biologically characterize, and attenuate the resulting
products. Ultimately, these data should contribute to the life
cycle assessment of various treatment trains to better balance
the overall financial and energy costs versus actual improved
protection of environmental and public health.
We note that although we have focused our discussion here
upon transformations of endogenous and synthetic steroids, we
believe concepts of conserved structure and conserved
bioactivity apply more generally to other contaminant classes.
For example, microbial transformation of nonylphenol
polyethoxylates results in enrichment of highly estrogenic
isomers.60 Other potent compounds whose transformation
products might merit prioritization or at least closer scrutiny
include chemotherapeutic agents, naturally occurring toxins,
and allelochemicals. In particular, many pharmaceuticals can
occur as enantiomers: mirror image, nonsuperimposable
isomers with surprisingly distinct bioactivity. Treatment
processes can selectively transform one enantiomer or
potentially result in interconversion,61 with both cases likely
to result in conserved bioactivity in effluent. Finally, rather than
conserved bioactivity there exist several examples where
transformation of seemingly benign substances produces
more bioactive or even toxic transformation products.
Brinkmann et al.62 recently demonstrated the development of
ER binding capabilities for hydroxylated biotransformation
products of heterocyclic aromatic hydrocarbons whose parent
structures have no intrinsic ER activity. Similar are reports63 of
genotoxic and mutagenic transformation products arising from
use of medium pressure UV (polychromatic UV) in the
presence of NOM and nitrate.
In summary, it is clear that environmental fate approaches
originally designed for persistent or acute toxicants may not be
equally effective for reactive contaminants that induce chronic
or sublethal effects. Persistence itself is not an adverse outcome,
merely a risk factor, and the critical issue for prioritizing
contaminant occurrence is a strong relationship between
bioactivity and potential adverse effects on organisms. As a
community, we may need to refine our approach to evaluating
environmental fate toward a greater focus on biological hazard
to account for inherent challenges posed by potent bioactive
contaminants and their transformation products. Moreover, we
should not think of bioactive contaminants, including steroids
and many other pharmaceuticals, as lone islets of bioactivity in
a surrounding sea of benign structures. Rather, they are islands
among larger archipelagos of bioactivity linked together by
structural commonalities. Environmental transformation pro-
cesses will in some cases allow for stealthy movements between
these islands, and this possibility should not be neglected
because these movements provide pathways to unintended
consequences. Many factors ultimately affected the choice of
which individual bioactive structure was selected for the
commercial products that are eventually released into the
environment, but we also must consider their surrounding
families when we consider environmental hazard. Utilization of
effects driven bioanalytical techniques is probably the most
cautious and insightful approach to characterization of this
complex terrain.
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